METTL14 overexpression alleviates neuronal ferroptosis in Alzheimer's disease by stabilizing PRDX6 mRNA
Background
Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, is increasingly recognized as a critical contributor to the pathogenesis and progression of Alzheimer's disease (AD). Current therapeutic strategies for AD primarily focus on symptomatic relief or amyloid/tau pathology, often failing to halt neurodegeneration. Understanding the precise mechanisms of ferroptosis in AD could unlock novel therapeutic targets. This study investigates the role of methyltransferase-like 14 (METTL14), an m6A RNA methyltransferase, in modulating neuronal ferroptosis within the context of AD pathology.
Study Design
Researchers simulated Alzheimer's disease in vitro using amyloid beta 1-42 oligomer-treated SH-SY5Y cells. Ferroptosis was assessed by measuring reactive oxygen species (ROS), malonaldehyde, glutathione, Fe2+ levels, and ferroptosis-related proteins. Cell viability was determined via Cell Counting Kit-8 assay. Total RNA N6-methyladenosine (m6A) levels were quantified, and peroxiredoxin 6 (PRDX6) m6A levels were analyzed using m6A RNA immunoprecipitation. The binding of METTL14 to PRDX6 was confirmed by a dual-luciferase reporter assay. Interventions included METTL14 overexpression and sh-METTL14 knockdown.
Results
Levels of METTL14 were consistently decreased in the serum of Alzheimer's disease patients and in the in-vitro AD model, with serum levels correlating with the degree of cognitive impairment. Overexpression of METTL14 significantly inhibited amyloid beta 1-42 oligomer-induced ferroptosis and cytotoxicity in SH-SY5Y cells. Mechanistically, METTL14-mediated m6A modification was found to increase PRDX6 mRNA stability, leading to the inactivation of the ROS-apoptosis signal-regulating kinase 1/p38 pathway. This pathway modulation is crucial for neuroprotection. > Rescue experiments further demonstrated that PRDX6 overexpression effectively reversed sh-METTL14-induced ferroptosis and neurotoxicity, underscoring the critical role of PRDX6 in this protective mechanism.
Key Findings
- METTL14 levels were decreased in AD patient serum and in vitro AD models, correlating with cognitive impairment.
- METTL14 overexpression significantly inhibited amyloid beta-induced neuronal ferroptosis and cytotoxicity.
- METTL14-mediated
m6Amodification increasedPRDX6mRNA stability. - Increased
PRDX6stability inactivated theROS-ASK1/p38pathway, providing neuroprotection. PRDX6overexpression reversedsh-METTL14-induced ferroptosis and neurotoxicity.
Why It Matters
This study identifies METTL14 as a crucial regulator of neuronal ferroptosis in Alzheimer's disease, offering a novel mechanistic insight into AD pathology. For researchers and biohackers, understanding the m6A modification pathway, particularly involving METTL14 and PRDX6, opens new avenues for therapeutic development beyond traditional amyloid/tau targets. Modulating METTL14 activity or enhancing PRDX6 stability could offer a novel neuroprotective strategy for Alzheimer's disease. While this is an in-vitro finding, it provides a strong rationale for exploring upstream regulators of ferroptosis in vivo, potentially leading to future drug candidates that target m6A machinery or PRDX6 expression to delay AD progression.
alzheimers-disease
ferroptosis
m6a-modification
mettl14
prdx6
neuroprotection